Blockchain Registration Transaction Record

Regentis Targets $3B Market with Off-the-Shelf Knee Cartilage Repair

Regentis Biomaterials aims to disrupt the $3B knee cartilage repair market with GelrinC, an off-the-shelf solution showing 100% greater pain improvement vs. microfracture. Phase III trial underway.

This news matters because knee cartilage damage affects millions, and current treatments are often ineffective or require complex cell-based therapies. GelrinC(R) offers a simpler, faster, and cheaper option with superior pain relief, potentially transforming patient outcomes and reducing healthcare costs. For investors, Regentis is at a pivotal stage with multiple catalysts that could drive significant value.